Does the media prefer DRUG or KROS?

In the previous week, Keros Therapeutics had 18 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 21 mentions for Keros Therapeutics and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat Keros Therapeutics' score of -0.11 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CADL or KROS?

In the previous week, Keros Therapeutics had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 21 mentions for Keros Therapeutics and 6 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of -0.08 beat Keros Therapeutics' score of -0.11 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PHAR or KROS?

In the previous week, Keros Therapeutics had 11 more articles in the media than Pharming Group. MarketBeat recorded 21 mentions for Keros Therapeutics and 10 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.32 beat Keros Therapeutics' score of -0.11 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor KROS or RIGL?

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Keros Therapeutics. MarketBeat recorded 25 mentions for Rigel Pharmaceuticals and 21 mentions for Keros Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.27 beat Keros Therapeutics' score of -0.11 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Rigel Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AURA or KROS?

In the previous week, Keros Therapeutics had 17 more articles in the media than Aura Biosciences. MarketBeat recorded 21 mentions for Keros Therapeutics and 4 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.70 beat Keros Therapeutics' score of -0.11 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Keros Therapeutics (KROS) Competitors

$11.18 +0.03 (+0.26%)

As of 09:30 AM Eastern

Compare

KROS vs. DRUG, CADL, PHAR, RIGL, and AURA

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Bright Minds Biosciences (DRUG), Candel Therapeutics (CADL), Pharming Group (PHAR), Rigel Pharmaceuticals (RIGL), and Aura Biosciences (AURA). These companies are all part of the "biotechnology" industry.

How does Keros Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Keros Therapeutics had 18 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 21 mentions for Keros Therapeutics and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat Keros Therapeutics' score of -0.11 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bright Minds Biosciences currently has a consensus target price of $143.83, indicating a potential upside of 83.13%. Keros Therapeutics has a consensus target price of $20.50, indicating a potential upside of 83.38%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Keros Therapeutics has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

Bright Minds Biosciences has a beta of -5.27, meaning that its share price is 627% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Bright Minds Biosciences' return on equity of -20.58% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Summary

Bright Minds Biosciences and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Candel Therapeutics has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

In the previous week, Keros Therapeutics had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 21 mentions for Keros Therapeutics and 6 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of -0.08 beat Keros Therapeutics' score of -0.11 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Candel Therapeutics presently has a consensus target price of $18.57, indicating a potential upside of 75.87%. Keros Therapeutics has a consensus target price of $20.50, indicating a potential upside of 83.38%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Summary

Keros Therapeutics beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Pharming Group has a net margin of 2.51% compared to Keros Therapeutics' net margin of -256.60%. Pharming Group's return on equity of 3.40% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

In the previous week, Keros Therapeutics had 11 more articles in the media than Pharming Group. MarketBeat recorded 21 mentions for Keros Therapeutics and 10 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.32 beat Keros Therapeutics' score of -0.11 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pharming Group currently has a consensus target price of $38.67, suggesting a potential upside of 257.33%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 83.38%. Given Pharming Group's higher probable upside, equities analysts clearly believe Pharming Group is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Keros Therapeutics has lower revenue, but higher earnings than Pharming Group. Keros Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.04	$2.85M	$0.12	90.18
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

Pharming Group has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Pharming Group beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Keros Therapeutics' net margin of -256.60%. Rigel Pharmaceuticals' return on equity of 22.95% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A
Rigel Pharmaceuticals	$294.28M	2.55	$367.02M	$16.32	2.48

Keros Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Keros Therapeutics. MarketBeat recorded 25 mentions for Rigel Pharmaceuticals and 21 mentions for Keros Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.27 beat Keros Therapeutics' score of -0.11 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 83.38%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 34.57%. Given Keros Therapeutics' higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Rigel Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Rigel Pharmaceuticals beats Keros Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Aura Biosciences presently has a consensus target price of $20.50, indicating a potential upside of 159.17%. Keros Therapeutics has a consensus target price of $20.50, indicating a potential upside of 83.38%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Keros Therapeutics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

Aura Biosciences has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Keros Therapeutics had 17 more articles in the media than Aura Biosciences. MarketBeat recorded 21 mentions for Keros Therapeutics and 4 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.70 beat Keros Therapeutics' score of -0.11 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aura Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Summary

Keros Therapeutics beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$221.10M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.01	9.02	270.57	25.05
Price / Sales	0.91	1,291.29	659.56	107.93
Price / Cash	2.46	44.95	28.89	37.44
Price / Book	0.72	17.52	11.20	6.43
Net Income	$87.01M	-$13.25M	$3.45B	$348.10M
7 Day Performance	10.57%	5.02%	3.39%	2.66%
1 Month Performance	-5.26%	-2.12%	-0.72%	-0.85%
1 Year Performance	-18.58%	61.49%	77.42%	23.96%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.0902 of 5 stars	$11.18 +0.3%	$20.50 +83.4%	-18.8%	$221.10M	$244.06M	N/A	100	Earnings Report Analyst Upgrade Gap Down
DRUG Bright Minds Biosciences	2.3143 of 5 stars	$80.80 +1.0%	$143.83 +78.0%	+104.4%	$778.57M	N/A	N/A	N/A	Upcoming Earnings Gap Up
CADL Candel Therapeutics	2.5693 of 5 stars	$10.58 +1.1%	$18.57 +75.5%	+75.9%	$766.41M	N/A	N/A	60	Upcoming Earnings Analyst Upgrade
PHAR Pharming Group	3.7521 of 5 stars	$10.69 +0.0%	$38.67 +261.9%	-18.0%	$755.56M	$376.13M	89.04	280	Analyst Forecast
RIGL Rigel Pharmaceuticals	4.313 of 5 stars	$39.22 -3.1%	$54.50 +39.0%	+26.7%	$748.96M	$294.28M	2.40	160	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. DRUG, CADL, PHAR, RIGL, and AURA

How does Keros Therapeutics compare to Bright Minds Biosciences?

Summary

How does Keros Therapeutics compare to Candel Therapeutics?

Summary

How does Keros Therapeutics compare to Pharming Group?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. DRUG, CADL, PHAR, RIGL, and AURA

How does Keros Therapeutics compare to Bright Minds Biosciences?

Do insiders and institutionals believe in DRUG or KROS?

Does the media prefer DRUG or KROS?

Do analysts rate DRUG or KROS?

Which has higher earnings & valuation, DRUG or KROS?

Which has more risk and volatility, DRUG or KROS?

Is DRUG or KROS more profitable?

Summary

How does Keros Therapeutics compare to Candel Therapeutics?

Which has more volatility and risk, CADL or KROS?

Which has preferable valuation & earnings, CADL or KROS?

Does the media prefer CADL or KROS?

Do analysts recommend CADL or KROS?

Do institutionals and insiders have more ownership in CADL or KROS?

Is CADL or KROS more profitable?

Summary

How does Keros Therapeutics compare to Pharming Group?

Is PHAR or KROS more profitable?

Does the media refer more to PHAR or KROS?

Do analysts prefer PHAR or KROS?

Which has higher earnings and valuation, PHAR or KROS?

Which has more risk & volatility, PHAR or KROS?

Do institutionals & insiders hold more shares of PHAR or KROS?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Do insiders and institutionals have more ownership in KROS or RIGL?

Is KROS or RIGL more profitable?

Which has higher valuation & earnings, KROS or RIGL?

Which has more risk and volatility, KROS or RIGL?

Does the media favor KROS or RIGL?

Do analysts rate KROS or RIGL?

Summary

How does Keros Therapeutics compare to Aura Biosciences?

Do analysts recommend AURA or KROS?

Which has better valuation & earnings, AURA or KROS?

Is AURA or KROS more profitable?

Do insiders and institutionals believe in AURA or KROS?

Does the media favor AURA or KROS?

Which has more risk & volatility, AURA or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools